Literature DB >> 12750398

Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Xue-Feng Bai1, Jinqing Liu, Ou Li, Pan Zheng, Yang Liu.   

Abstract

It is established that mutations in viral antigenic epitopes, or antigenic drifts, allow viruses to escape recognition by both Ab's and T lymphocytes. It is unclear, however, whether tumor cells can escape immune recognition via antigenic drift. Here we show that adoptive therapy with both monoclonal and polyclonal transgenic CTLs, specific for a natural tumor antigen, P1A, selects for multiple mutations in the P1A antigenic epitope. These mutations severely diminish T cell recognition of the tumor antigen by a variety of mechanisms, including modulation of MHC:peptide interaction and TCR binding to MHC:peptide complex. These results provide the first evidence for tumor evasion of T cell recognition by antigenic drift, and thus have important implications for the strategy of tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750398      PMCID: PMC155049          DOI: 10.1172/JCI17656

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.

Authors:  P Shrikant; A Khoruts; M F Mescher
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

Review 3.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

4.  CD4+ T-cell-epitope escape mutant virus selected in vivo.

Authors:  A Ciurea; L Hunziker; M M Martinic; A Oxenius; H Hengartner; R M Zinkernagel
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

Review 5.  TAP off--tumors on.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  1997-06

6.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

7.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

Authors:  J Banchereau; A K Palucka; M Dhodapkar; S Burkeholder; N Taquet; A Rolland; S Taquet; S Coquery; K M Wittkowski; N Bhardwaj; L Pineiro; R Steinman; J Fay
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

8.  Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.

Authors:  X F Bai; J Bender; J Liu; H Zhang; Y Wang; O Li; P Du; P Zheng; Y Liu
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

9.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

Authors:  P G Coulie; V Karanikas; D Colau; C Lurquin; C Landry; M Marchand; T Dorval; V Brichard; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

10.  Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.

Authors:  G B Beck-Engeser; P A Monach; D Mumberg; F Yang; S Wanderling; K Schreiber; R Espinosa; M M Le Beau; S C Meredith; H Schreiber
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

View more
  40 in total

1.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

2.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

3.  Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients.

Authors:  Yi Shao; Zhen-Yuan Sun; Shi-Wei Sun; Yi Zhao; Wan Yee Sin; Yan-Hua Yuan; Andrew J Simpson; Lloyd J Old; Xin-Ting Sang; Yi-Lei Mao; Yong Xie; Jie-Fu Huang; Hai-Tao Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-25       Impact factor: 4.553

4.  MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.

Authors:  Sang-Yeul Lee; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice.

Authors:  Kenneth F May; Kenneth Lute; Ergun Kocak; Shahab Abdessalam; Lijie Yin; Ou Li; Zhen Guan; Gary Philips; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

6.  Interleukin-27 signalling induces stem cell antigen-1 expression in T lymphocytes in vivo.

Authors:  Zhihao Liu; Lisha Wu; Jing Zhu; Xiaotong Zhu; Jianmin Zhu; Jin-Qing Liu; Jianchao Zhang; Jonathan P Davis; Sanjay Varikuti; Abhay R Satoskar; Jie Zhou; Ming-Song Li; Xue-Feng Bai
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

7.  IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.

Authors:  L-X Wang; F Talebian; J-Q Liu; M Khattabi; L Yu; X-F Bai
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

8.  Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases.

Authors:  Bill T Storey; H Keith Pittman; Joseph F Christian; Carl E Haisch; Kathryn M Verbanac
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

10.  Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Authors:  Matthew M Seavey; Yvonne Paterson
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.